Chris Twelves
Overview
Explore the profile of Chris Twelves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
3624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
West E, Sadoun A, Bendjama K, Erbs P, Smolenschi C, Cassier P, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39785814
Background: Effective treatment for patients with metastatic cancer is limited, particularly for colorectal cancer patients with metastatic liver lesions (mCRC), where accessibility to numerous tumours is essential for favourable clinical...
2.
Hanna D, Merrick S, Ghose A, Devlin M, Yang D, Phillips E, et al.
Br J Cancer
. 2024 Apr;
130(12):1916-1920.
PMID: 38658782
Background: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG)...
3.
Braun I, Bohlke K, Abrams D, Anderson H, Balneaves L, Bar-Sela G, et al.
J Clin Oncol
. 2024 Mar;
42(13):1575-1593.
PMID: 38478773
Purpose: To guide clinicians, adults with cancer, caregivers, researchers, and oncology institutions on the medical use of cannabis and cannabinoids, including synthetic cannabinoids and herbal cannabis derivatives; single, purified cannabinoids;...
4.
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect
. 2023 Apr;
87(1):18-26.
PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
5.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2023 Apr;
86(5):540-541.
PMID: 37055303
No abstract available.
6.
Oswald A, Symeonides S, Wheatley D, Chan S, Brunt A, McAdam K, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(1):35-46.
PMID: 36859649
Purpose: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and...
7.
Schramm M, Currie S, Lee M, Livermore L, Solanki S, Mathew R, et al.
J Neurooncol
. 2023 Feb;
161(3):451-467.
PMID: 36757526
Introduction: Brain tumors cause morbidity and mortality in part through peritumoral brain edema. The current main treatment for peritumoral brain edema are corticosteroids. Due to the increased recognition of their...
8.
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, et al.
J Bone Oncol
. 2022 Jul;
35:100442.
PMID: 35800293
Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of...
9.
Franzoi M, Procter M, Twelves C, Ponde N, Eiger D, Emond O, et al.
Ecancermedicalscience
. 2022 Jun;
16:1379.
PMID: 35702414
Background: Geographic location and national income may influence access to innovation in healthcare. We aimed to study if geographical location and national income influenced the timelines to activate the global...
10.
Howell S, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al.
Lancet Oncol
. 2022 Jun;
23(7):851-864.
PMID: 35671774
Background: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared...